PET imaging of patients with non-small cell lung cancer employing an EGF receptor targeting drug as tracer
Memon, A A LU
; Weber, B
; Winterdahl, M
; Jakobsen, S
; Meldgaard, P
; Madsen, H H T
; Keiding, S
; Nexo, E
and Sorensen, B S
(2011)
In British Journal of Cancer
105(12).
p.5-1850
- Abstract
BACKGROUND: We have previously developed (11)C-erlotinib as a new positron emission tomography (PET) tracer and shown that it accumulates in epidermal growth factor receptor (EGFR)-positive lung cancer xenografts in mice. Here, we present a study in patients with non-small cell lung cancer (NSCLC) investigating the feasibility of (11)C-erlotinib PET as a potential method for the identification of lung tumours accumulating erlotinib.
METHODS: Thirteen patients with NSCLC destined for erlotinib treatment were examined by contrast-enhanced computed tomography (CT), (11)C-erlotinib PET/low-dose CT and (18)F-fluoro-2-deoxy-D-glucose ((18)F-FDG) PET/low-dose CT before start of the erlotinib treatment. After 12 weeks treatment, they were... (More)
BACKGROUND: We have previously developed (11)C-erlotinib as a new positron emission tomography (PET) tracer and shown that it accumulates in epidermal growth factor receptor (EGFR)-positive lung cancer xenografts in mice. Here, we present a study in patients with non-small cell lung cancer (NSCLC) investigating the feasibility of (11)C-erlotinib PET as a potential method for the identification of lung tumours accumulating erlotinib.
METHODS: Thirteen patients with NSCLC destined for erlotinib treatment were examined by contrast-enhanced computed tomography (CT), (11)C-erlotinib PET/low-dose CT and (18)F-fluoro-2-deoxy-D-glucose ((18)F-FDG) PET/low-dose CT before start of the erlotinib treatment. After 12 weeks treatment, they were examined by (18)F-FDG PET/contrast-enhanced CT for the assessment of clinical response.
RESULTS: Of the 13 patients included, 4 accumulated (11)C-erlotinib in one or more of their lung tumours or lymph-node metastases. Moreover, (11)C-erlotinib PET/CT identified lesions that were not visible on (18)F-FDG PET/CT. Of the four patients with accumulation of (11)C-erlotinib, one died before follow-up, whereas the other three showed a positive response to erlotinib treatment. Three of the nine patients with no accumulation died before follow-up, four showed progressive disease while two had stable disease after 12 weeks of treatment.
CONCLUSION: Our data show a potential for (11)C-erlotinib PET/CT for visualizing NSCLC lung tumours, including lymph nodes not identified by (18)F-FDG PET/CT. Large clinical studies are now needed to explore to which extent pre-treatment (11)C-erlotinib PET/CT can predict erlotinib treatment response.
(Less)
- author
- Memon, A A
LU
; Weber, B
; Winterdahl, M
; Jakobsen, S
; Meldgaard, P
; Madsen, H H T
; Keiding, S
; Nexo, E
and Sorensen, B S
- publishing date
- 2011-12-06
- type
- Contribution to journal
- publication status
- published
- subject
- keywords
- Adult, Aged, Animals, Carcinoma, Non-Small-Cell Lung/diagnostic imaging, ErbB Receptors/metabolism, Female, Humans, Lung Neoplasms/diagnostic imaging, Male, Mice, Middle Aged, Multimodal Imaging, Positron-Emission Tomography, Tomography, X-Ray Computed, Treatment Outcome
- in
- British Journal of Cancer
- volume
- 105
- issue
- 12
- pages
- 6 pages
- publisher
- Nature Publishing Group
- external identifiers
-
- scopus:84856053461
- pmid:22095231
- ISSN
- 1532-1827
- DOI
- 10.1038/bjc.2011.493
- language
- English
- LU publication?
- no
- id
- 10e44474-58bb-4c30-b480-49cfd420869f
- date added to LUP
- 2019-11-22 16:17:01
- date last changed
- 2024-04-17 00:00:41
@article{10e44474-58bb-4c30-b480-49cfd420869f,
abstract = {{<p>BACKGROUND: We have previously developed (11)C-erlotinib as a new positron emission tomography (PET) tracer and shown that it accumulates in epidermal growth factor receptor (EGFR)-positive lung cancer xenografts in mice. Here, we present a study in patients with non-small cell lung cancer (NSCLC) investigating the feasibility of (11)C-erlotinib PET as a potential method for the identification of lung tumours accumulating erlotinib.</p><p>METHODS: Thirteen patients with NSCLC destined for erlotinib treatment were examined by contrast-enhanced computed tomography (CT), (11)C-erlotinib PET/low-dose CT and (18)F-fluoro-2-deoxy-D-glucose ((18)F-FDG) PET/low-dose CT before start of the erlotinib treatment. After 12 weeks treatment, they were examined by (18)F-FDG PET/contrast-enhanced CT for the assessment of clinical response.</p><p>RESULTS: Of the 13 patients included, 4 accumulated (11)C-erlotinib in one or more of their lung tumours or lymph-node metastases. Moreover, (11)C-erlotinib PET/CT identified lesions that were not visible on (18)F-FDG PET/CT. Of the four patients with accumulation of (11)C-erlotinib, one died before follow-up, whereas the other three showed a positive response to erlotinib treatment. Three of the nine patients with no accumulation died before follow-up, four showed progressive disease while two had stable disease after 12 weeks of treatment.</p><p>CONCLUSION: Our data show a potential for (11)C-erlotinib PET/CT for visualizing NSCLC lung tumours, including lymph nodes not identified by (18)F-FDG PET/CT. Large clinical studies are now needed to explore to which extent pre-treatment (11)C-erlotinib PET/CT can predict erlotinib treatment response.</p>}},
author = {{Memon, A A and Weber, B and Winterdahl, M and Jakobsen, S and Meldgaard, P and Madsen, H H T and Keiding, S and Nexo, E and Sorensen, B S}},
issn = {{1532-1827}},
keywords = {{Adult; Aged; Animals; Carcinoma, Non-Small-Cell Lung/diagnostic imaging; ErbB Receptors/metabolism; Female; Humans; Lung Neoplasms/diagnostic imaging; Male; Mice; Middle Aged; Multimodal Imaging; Positron-Emission Tomography; Tomography, X-Ray Computed; Treatment Outcome}},
language = {{eng}},
month = {{12}},
number = {{12}},
pages = {{5--1850}},
publisher = {{Nature Publishing Group}},
series = {{British Journal of Cancer}},
title = {{PET imaging of patients with non-small cell lung cancer employing an EGF receptor targeting drug as tracer}},
url = {{http://dx.doi.org/10.1038/bjc.2011.493}},
doi = {{10.1038/bjc.2011.493}},
volume = {{105}},
year = {{2011}},
}